SiBone (NASDAQ:SIBN) Shares Acquired by Legato Capital Management LLC

Legato Capital Management LLC boosted its position in SiBone (NASDAQ:SIBN - Free Report) by 58.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 99,356 shares of the company's stock after purchasing an additional 36,649 shares during the period. Legato Capital Management LLC owned about 0.23% of SiBone worth $1,394,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its position in SiBone by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares during the period. Silvercrest Asset Management Group LLC lifted its position in shares of SiBone by 21.9% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after acquiring an additional 350,970 shares during the period. Paradigm Capital Management Inc. NY lifted its position in shares of SiBone by 5.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock valued at $19,432,000 after acquiring an additional 69,831 shares during the period. Nuveen Asset Management LLC lifted its position in shares of SiBone by 17.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after acquiring an additional 190,830 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of SiBone by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after acquiring an additional 9,847 shares during the period. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Truist Financial raised their price objective on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th.

Insider Transactions at SiBone

In other SiBone news, Director Jeffrey W. Dunn sold 3,377 shares of SiBone stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total value of $64,331.85. Following the completion of the sale, the director directly owned 17,354 shares of the company's stock, valued at approximately $330,593.70. The trade was a 16.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura Francis sold 5,412 shares of SiBone stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $19.49, for a total transaction of $105,479.88. Following the completion of the sale, the chief executive officer directly owned 490,987 shares of the company's stock, valued at $9,569,336.63. The trade was a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 101,702 shares of company stock worth $1,866,404 in the last three months. 4.00% of the stock is currently owned by company insiders.

SiBone Price Performance

Shares of SIBN traded down $0.11 during mid-day trading on Friday, reaching $17.25. 208,797 shares of the company's stock were exchanged, compared to its average volume of 419,765. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21. The company has a 50-day simple moving average of $18.05 and a two-hundred day simple moving average of $16.54. SiBone has a 52-week low of $11.70 and a 52-week high of $20.05. The company has a market cap of $735.11 million, a price-to-earnings ratio of -26.95 and a beta of 0.93.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. On average, sell-side analysts predict that SiBone will post -0.78 EPS for the current fiscal year.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.